Responses to polymeric lung volume reduction (PLVR) therapy at 6 months in patients with GOLD stage III emphysema

F. Herth, R. Eberhardt, F. Stanzel, R. Bonett, J. Behr, B. Schmidt, H. Magnussen (Hemer, Bad Berka, Munich, Berlin, Germany)

Source: Annual Congress 2010 - Interventions for obstructive lung diseases
Session: Interventions for obstructive lung diseases
Session type: Oral Presentation
Number: 3417
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Herth, R. Eberhardt, F. Stanzel, R. Bonett, J. Behr, B. Schmidt, H. Magnussen (Hemer, Bad Berka, Munich, Berlin, Germany). Responses to polymeric lung volume reduction (PLVR) therapy at 6 months in patients with GOLD stage III emphysema. Eur Respir J 2010; 36: Suppl. 54, 3417

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 171s
Year: 2006

Effect of biologic lung volume reduction (BLVR) therapy on BODE at 6 and 12 weeks
Source: Annual Congress 2008 - COPD
Year: 2008


Predicted versus observed postoperative lung function six months after lung resection: A comparation between patients with and without COPD
Source: International Congress 2019 – Exploring the lungs in various pathophysiological conditions
Year: 2019

Polymeric lung volume reduction (PLVR) therapy for advanced homogeneous emphysema
Source: Annual Congress 2010 - New toys, old problems: extrapleural lung volume reduction, sedation and comfort in bronchoscopy
Year: 2010

Estimated postoperative pulmonary function and 6 months recovery for lobectomized lung cancer patients with and without COPD
Source: International Congress 2016 – Surgical strategy for complex diseases
Year: 2016

Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Early versus late pulmonary rehabilitation (PR) following treatment for inoperable nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation
Year: 2013



Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 70s
Year: 2006

Effects of a combination of pulmonary rehabilitation (PR) and non invasive ventilation (NIV) in patients with advanced interstitial lung disease (ILD)
Source: Annual Congress 2009 - Noninvasive ventilation in chronic respiratory failure
Year: 2009


A dose ranging study of the aeris polymeric lung volume reduction (PLVR) system in patients with advanced upper lobe predominant (ULP) emphysema
Source: Annual Congress 2009 - Treatment beyond inhalers
Year: 2009


Relation of various parameters to the survival rate in stage 0 to stage IIa chronic obstructive pulmonary disease (COPD) according to the GOLD guidelines
Source: Eur Respir J 2003; 22: Suppl. 45, 578s
Year: 2003

Noninvasive ventilation (NIV) after lung resection (LR) to prevent respiratory complications (RCs) in COPD patients (pts) (POPVNI trial)
Source: Annual Congress 2011 - Noninvasive ventilation in the acute setting: education, organisation, H1N1, paediatrics, weaning, diagnostic procedures and special considerations
Year: 2011

A single center experience with lung volume reduction coil (LVR-coil) treatment of patients with advanced emphysema. Effectiveness and complications after 1 year
Source: International Congress 2016 – Endoscopic lung volume reduction II
Year: 2016

Results of unilateral lung volume reduction surgery (LVRS) in eight patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 107s
Year: 2006

Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015


Effect of polymeric lung volume reduction (PLVR) therapy on composite COPD outcome measures
Source: Annual Congress 2010 - COPD: symptoms and staging
Year: 2010



6 and 12 month outcomes following RePneu bronchoscopic lung volume reduction coil treatment
Source: Annual Congress 2013 –Bronchoscopic treatment of COPD and asthma: where are we going?
Year: 2013


Changes in lung function and comorbidity in patients with COPD over 4 to 10 years of follow-up
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013

Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017


Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC).
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017